采用新型偶联剂ＳＡＴＡ，将抗人体大肠癌的单克隆抗体与载有紫杉醇的脂质体偶联制成免疫脂质体。检测结果显示，脂质体稳定性良好，４℃存放１０ｄ，内含物无明显渗漏。制成免疫脂质体后，单抗免疫活性不丧失。体外细胞毒实验结果显示，紫杉醇免疫脂质体对细胞生长的抑制作用有明显的靶向专一性，对人大肠癌细胞的体外细胞毒作用优于普通脂质体和游离药物，ＩＣ５０分别为两者的６．７０和８８．７倍，对非靶细胞的作用与普通脂质体相似 The novel coupling agent SATA was used to couple anti-human colorectal cancer monoclonal antibodies with paclitaxel-loaded liposomes into immunoliposomes. The test results showed that the liposomes had good stability and stored at 4°C for 10 days. There was no obvious leakage of the contents. After being made into immunoliposomes, the monoclonal antibody immunoreactivity was not lost. The results of in vitro cytotoxicity test showed that paclitaxel immunoliposomes had a distinct targeting specificity for cell growth inhibition, and the cytotoxicity against human colorectal cancer cells was superior to that of common liposomes and free drugs. IC50 was 6.70 and 88.7-fold of both, similar to normal liposomes for non-target cells